Evaluation of DHFR Inhibition and Antimicrobial Activity of Some Newly Synthesized Quinazolin-4(3H)-one Scaffold Coupled with Benzylidene and Ethylidene Amino Motifs
1★, 2, 3★ Corresponding author
- 1Department of Pharmaceutical Chemistry, Dattakala College of Pharmacy, Swami Chincholi, Pune, Maharashtra, INDIA.
- 2Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, INDIA.
- 3Progressive Education Society’s Modern College of Pharmacy, Nigdi, Pune, Maharashtra, INDIA.
CORRESPONDENCE
Sunil Harer
Department of Pharmaceutical Chemistry, Dattakala College of Pharmacy, Swami Chincholi, Pune, Maharashtra, INDIA.
Received: 16-08-2022; Revised: 18-09-2022; Accepted: 12-10-2022.
Volume 13, Issue 1 · pp. 62-73 · 2022 · DOI: 10.5530/223097131749
ABSTRACT
Objectives: Substituted quinazolin-4(3H)-ones at position-3 with phenyl ring, heterocycles and aliphatic moieties, were reported to impart antimicrobial activities. In light of this, we have attempted to prepare a novel series of 2-pheny-3-substituted quinazolin-4(3H)-ones fused with an azomethine (-CH=N-) connection to Benzylidene and ethylidene motifs. Each of these motifs underwent testing to determine whether it could inhibit in-vitro microbial DHFR and the subsequent antimicrobial action.Materials and Methods: The synthesized 2-phenyl-3- substituted quinazolin-4(3H)-ones were characterized by FT-IR, 1H-NMR, 13C-NMR, ESI-MS and elemental (C, H, N, O and X=halogen) analysis. Evaluated results of in-vitro microbial DHFR inhibition are compared with the reported drug trimethoprim. Agar disc diffusion method was used for in-vitro antimicrobial activity, performed against pathogenic Gram-positive and Gram- negative bacteria like Staphylococcus aureus, Bacillus subtilis, and Escherichia coli, Pseudomonas aeruginosa respectively, and fungi like Candida albicans, and Aspergillus niger.Results: Docking analysis of ligands with DHFR (PDB=2W3M) has shown strong hydrophobic binding interaction and confirmed a perfect fit into the active domain of the target protein. Possible antimicrobial activity was induced from microbial DHFR inhibition. The results of the tests are compared with gentamycin, ciprofloxacin, and clotrimazole. Compounds with potent antibacterial activity were QI-j, and QII-f (MIC=0.1-0.2µg/mL), and moderately active compounds were QIa-d, QIl-m, QIII-d, and QIIIe-f (MIC=0.5-2.0µg/mL). Compounds exhibited potent antifungal activity were QI-c, QII-b, and QIII-f (MIC=0.1-0.2µg/mL), moderately active compounds were QIc-e, QI-g, QIm-n, QII-d, QIII-b, and QIII-e (MIC=0.5-2.0µg/mL).Conclusion: Particularly test compounds have produced DHFR inhibition in a range of 4-24µM as compared with trimethoprim (IC50=10 µM). Benzylidene and ethylidene moieties attached to the quinazolin-4(3H)-one had contributed to this activity. Present series of substituted quinazolin-4(3H)-ones provide a path for the design and development of newer antimicrobial agents in the treatment of deadly pathogenic infections.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Harer, S., Bhatia, M., & Sonar, P. (2022). Evaluation of DHFR Inhibition and Antimicrobial Activity of Some Newly Synthesized Quinazolin-4(3H)-one Scaffold Coupled with Benzylidene and Ethylidene Amino Motifs. International Journal of Pharmaceutical Investigation, 13(1), 62-73. https://doi.org/10.5530/223097131749
Copyright and licence
© 2022 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0